Skip to main content

Table 1 Patient Demographic and Clinical Characteristics

From: Correlation between spleen density and prognostic outcomes in patients with colorectal cancer after curative resection

Factors

Total (n = 212)

non-DROSD (n = 189)

DROSD (n = 23)

P-values

Age (years), Mean ± SD

69.45 ± 10.63

69.21 ± 10.56

71.39 ± 11.22

0.354

BMI (kg/cm2), Mean ± SD

22.19 ± 3.32

22.04 ± 3.12

23.40 ± 4.53

0.063

Surgical duration (min), Mean ± SD

174.21 ± 48.97

175.35 ± 50.05

164.78 ± 38.66

0.329

Length of postoperative hospital stay (day), Mean ± SD

16.49 ± 10.75

16.30 ± 11.23

18.09 ± 5.30

0.452

Gender, n (%)

   

0.137

 Male

140 (66.04)

128 (67.72)

12 (52.17)

 

 Female

72 (33.96)

61 (32.28)

11 (47.83)

 

Tumor size (cm), n (%)

   

0.324

 <4

75 (35.38)

69 (36.51)

6 (26.09)

 

 ≧4

137 (64.62)

120 (63.49)

17 (73.91)

 

Tumor location, n (%)

   

0.545

 Rectum

98 (46.23)

86 (45.50)

12 (52.17)

 

 Colon

114 (53.77)

103 (54.50)

11 (47.83)

 

TNM, n (%)

   

0.727

 I

31 (14.62)

29 (15.34)

2 (8.70)

 

 II

99 (46.7)

89 (47.09)

10 (43.48)

 

 III

70 (33.02)

60 (31.75)

10 (43.48)

 

 IV

12 (5.66)

11 (5.82)

1 (4.35)

 

Histologic type, n (%)

   

0.371

 Differentiateda

208 (98.11)

186 (98.41)

22 (95.65)

 

 Undifferentiatedb

4 (1.89)

3 (1.59)

1 (4.35)

 

Anemia, n (%)

   

0.179

 No

111 (52.36)

102 (53.97)

9 (39.13)

 

 Yes

101 (47.64)

87 (46.03)

14 (60.87)

 

Radiotherapy and chemotherapy, n (%)

   

0.041*

 No

156 (73.58)

135 (71.43)

21 (91.30)

 

 Yes

56 (26.42)

54 (28.57)

2 (8.70)

 

Previous abdominal surgery, n (%)

   

0.017*

 No

179 (84.43)

164 (86.77)

15 (65.22)

 

 Yes

33 (15.57)

25 (13.23)

8 (34.78)

 

Epidural anesthesia, n (%)

   

0.374

 No

186 (87.74)

164 (86.77)

22 (95.65)

 

 Yes

26 (12.26)

25 (13.23)

1 (4.35)

 

Laparoscopy-assisted operation, n (%)

   

0.001**

 No

116 (54.72)

96 (50.79)

20 (86.96)

 

 Yes

96 (45.28)

93 (49.21)

3 (13.04)

 

Enterostomy, n (%)

   

0.961

 No

179 (84.43)

159 (84.13)

20 (86.96)

 

 Yes

33 (15.57)

30 (15.87)

3 (13.04)

 

Combined resection, n (%)

   

0.664

 No

193 (91.04)

171 (90.48)

22 (95.65)

 

 Yes

19 (8.96)

18 (9.52)

1 (4.35)

 

WBC > 10 G/L, n (%)

   

1.000

 No

190 (89.62)

169 (89.42)

21 (91.30)

 

 Yes

22 (10.38)

20 (10.58)

2 (8.70)

 

Hypoalbuminemia, n (%)

   

0.088

 No

171 (80.66)

156 (82.54)

15 (65.22)

 

 Yes

41 (19.34)

33 (17.46)

8 (34.78)

 

CEA > 9.7 ng/mL, n (%)

   

0.038*

 No

165 (77.83)

151 (79.89)

14 (60.87)

 

 Yes

47 (22.17)

38 (20.11)

9 (39.13)

 

CA199 > 37 U/mL, n (%)

   

0.276

 No

178 (83.96)

161 (85.19)

17 (73.91)

 

 Yes

34 (16.04)

28 (14.81)

6 (26.09)

 

ASA score, n (%)

   

0.809

 ≦2

161 (75.94)

144 (76.19)

17 (73.91)

 

 >2

51 (24.06)

45 (23.81)

6 (26.09)

 

NSR2002score, n (%)

   

0.266

 <3

193 (91.04)

174 (92.06)

19 (82.61)

 

 ≧3

19 (8.96)

15 (7.94)

4 (17.39)

 

CCI score, n (%)

   

0.251

 0

116 (54.72)

106 (56.08)

10 (43.48)

 

 ≧1

96 (45.28)

83 (43.92)

13 (56.52)

 

Estimated blood loss > 300 ml, n (%)

   

1.000

 No

196 (92.45)

175 (92.59)

21 (91.30)

 

 Yes

16 (7.55)

14 (7.41)

2 (8.70)

 

Clavien-Dindo classification, n (%)

   

0.021*

 0-II

146 (68.87)

135 (71.43)

11 (47.83)

 

 III-V

66 (31.13)

54 (28.57)

12 (52.17)

 
  1. BMI body mass index, TNM Tumor Node Metastasis, ASA American Society of Anesthesiology, NRS2002 Nutritional Risk Screening 2002, CCI Charlson Comorbidity Index, WBC White Blood Cell, CEA Carcino Embryonic Antigen, CA199 Cancer Antigen 199.
  2. *p < 0.05, ** p < 0.01
  3. aUndifferentiated carcinomas include poorly differentiated adenocarcinomas, signet ring cell carcinomas, and mucinous carcinomas.
  4. bDifferentiated carcinomas include well or moderately differentiated, tubular or papillary adenocarcinomas.